|Brand name(s), other common name(s)||Tibsovo®|
|Drug type||Isocitrate dehydrogenase-1 (IDH1) inhibitor|
|How the drug is given||By mouth|
Indications and Usage
Ivosidenib is FDA approved for the treatment of acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test in:
- Adult patients with newly-diagnosed AML who are ≥ 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy
- Adult patients with relapsed or refractory AML
Side effects needing medical attention
Fatigue, increased number of leukocytes (white blood cells) (leukocytosis), joint pain, diarrhea, difficulty breathing, excess of fluid in cavities or tissues of the body (edema), nausea, painful inflammation and ulceration of the mucous membranes lining the digestive tract (mucositis), electrocardiogram QT prolonged, rash, fever, cough, and constipation.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.